Here's why the Resonance Health (ASX:RHT) share price rocketed

The Resonance Health share price rocketed more than 16% today before closing 5% higher. We take a look at what's stirring investor interest.

| More on:
Young doctor raising arms in air with hands in fists celebrating a new development

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Resonance Health Ltd (ASX: RHT) share price rocketed more than 16% today before closing 5% higher.

The booming share price moves come after the company emerged from a trading halt late this morning. This follows the release of an announcement on its medical device.

What did Resonance Health report to send its shares higher?

In a late morning ASX release, Resonance Health announced that it has received Australian Therapeutic Goods Administration (TGA) approval for its HepaFat-AI device. The device provides fully automated artificial intelligence software to assesses liver fat.

With the TGA approval, Resonance Health can now supply its device across Australia. The company had already received clearance from the United States Food & Drug Administration (FDA) in early December.

HepaFat-AI automatically analyses magnetic resonance imaging (MRI) data. Subsequently, this data assesses liver fat in patients to give physicians a new tool in assessing patients with confirmed or suspected fatty liver disease.

According to Resonance Health, doctors can use the device to monitor patients for a number of issues. This will include patients in weight loss programs and screening the livers of live donors for transplant suitability. Additionally, the device will monitor patients who have or are believed to have non-alcoholic fatty liver disease (NAFLD) or the more serious subtype, non-alcoholic steatohepatitis (NASH).

Resonance Health reports that "NAFLD affects up to 2.3 billion people, a figure expected to grow year-on-year. Of these, about 470 million people (or 20%) will develop NASH". NASH can lead to serious health consequences, including liver failure.

The company plans to market the device to radiologists and physicians involved in the routine clinical diagnosis and management of patients with confirmed or suspected fatty liver disease. However, it also sees a market with pharmaceutical companies engaged in NASH drug development.

Resonance Health says its work in machine learning to develop assistance tools for the medical sector is continuing.

Share price snapshot

Over the past 12 months, Resonance Health shares are up 2.5%. That compares to a 1% loss on the All Ordinaries Index (ASX: XAO).

Year-to-date, the Resonance Health share price is down 10.8%.

Should you invest $1,000 in Tpg Telecom Limited right now?

Before you buy Tpg Telecom Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Tpg Telecom Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Resonance Health Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A neon sign says 'Top Ten'.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rough trading day for ASX stocks this Monday.

Read more »

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Broker Notes

Bell Potter names more of the best ASX 200 stocks to buy in May

These stocks could be best buys this month according to the broker.

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

Oil worker using a smartphone in front of an oil rig.
Energy Shares

ASX 200 energy shares plunge on shock OPEC move

ASX 200 energy shares like Woodside and Santos are tumbling on Monday. Let’s find out why.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why 4DMedical, Gold Road, Syrah, and Tyro shares are racing higher today

These shares are starting the week strongly. But why?

Read more »

Rising gold share price represented by a green arrow on piles of gold block.
Gold

2 ASX gold stocks racing higher in Monday's sinking market

Investors are sending these ASX gold stocks flying higher on Monday. But why?

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why Brainchip, Helia Group, Reliance Worldwide, and Westpac shares are dropping today

These shares are starting the week in the red. But why?

Read more »

Man looking upwards contemplating which shares to buy
Broker Notes

CSL shares have climbed 10% since 11 April. Is it too late to buy?

What are analysts saying about this biotech giant after its recent rally? Let's find out.

Read more »